Effect of Metrofim and Vildagliptin in Type II diabetes
Автор:
Deepak Bhosle,Asmita Hingole and Vandana Bhosle, 104 стр., издатель:
"LAP Lambert Academic Publishing", ISBN:
9783659257858
Diabetes mellitus is a group of metabolic disorder characterized by hyperglycaemia and altered metabolism of lipid, protein and carbohydrate. In diabetes there is total or subtotal deficiency of insulin along incetine defice.Insulin and many oral hypoglycemic drugs and are available for the treatment of Type II still target HbA1c is not achived. Vildaglipton selective inhibitor of Dipeptidyl Peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of circulating Glucagon - like Peptide-1.It improves islet function in patients with type-2 diabetes by increasing both ? and ? cell responsiveness to glucose and decrease fasting plasma glucose (FPG) and postprandial glucose.Metformin is the most commonly prescribed first-line hypoglycaemic drug worldwide, but due to the progressive worsening of blood glucose control during the natural history of type-2 diabetes, combination therapy usually becomes necessary.Therefore, it was of interest to ascertain the efficacy and...
Под заказ: |
|
OZON.ru - 3890 руб.
|
Перейти
|
|
|